The report is available in English with a French summary - KCE

More documents

Recommendations

Info

108. Le Tiotropium dans le traitement des BronchoPneumopathies Chroniques Obstructives: Health Technology Assessment. D/2009/10.273/19 109. A propos de la valeur de l’EEG et des potentiels évoqués dans la pratique clinique. D/2009/10.273/22 110. La tomographie par émission de positrons en Belgique: une mise à jour. D/2009/10.273/25 111. Interventions pharmaceutiques et non pharmaceutiques dans la maladie d’Alzheimer : une évaluation rapide. D/2009/10.273/28 112. Politiques relatives aux maladies orphelines et aux médicaments orphelins. D/2009/10.273/31 113. Le volume des interventions chirurgicales et son impact sur le résultat : étude de faisabilité basée sur des données belges. D/2009/10.273/34. 114. Valves endobronchiales dans le traitement de l’emphysème pulmonaire avancé: un rapid Health Technology Assessment. D/2009/10.273/38 115. Organisation des soins palliatifs en Belgique. D/2009/10.273/41 116. Evaluation rapide des implants inter-épineux et des vis pédiculaires pour la stabilisation dynamique de la colonne vertébrale lombaire. D/2009/10.273/45 117. Utilisation des coagulomètres portables chez les patients sous anticoagulants oraux: Health technology Assesment. D/2009/10.273/48. 118. Avantages, désavantages et faisabilité de l’introduction de programmes “P4Q” en Belgique. D/2009/10.273/51. 119. Douleur cervicales atypiques: diagnostic et traitement. D/2009/10.273/55. 120. Comment assurer l’autosuffisance de la Belgique en dérivés stables du plasma? D/2009/10.273/58.
Page 1 and 2:
Comment assurer l’autosuffisance
Page 3 and 4:
Comment assurer l’autosuffisance
Page 5 and 6:
KCE Reports 120B Plasma i PRÉFACE
Page 7 and 8:
KCE Reports 120B Plasma iii MÉTHOD
Page 9 and 10:
KCE Reports 120B Plasma v En ce qui
Page 11 and 12:
KCE Reports 120B Plasma vii RECOMMA
Page 13 and 14:
KCE Reports 120 Plasma 1 Scientific
Page 15 and 16:
KCE Reports 120 Plasma 3 GLOSSARY A
Page 17 and 18:
KCE Reports 120 Plasma 5 1 INTRODUC
Page 19 and 20:
KCE Reports 120 Plasma 7 Focus: sta
Page 21 and 22:
KCE Reports 120 Plasma 9 Two techni
Page 23 and 24:
KCE Reports 120 Plasma 11 Therefore
Page 25 and 26:
KCE Reports 120 Plasma 13 FRENCH-SP
Page 27 and 28:
KCE Reports 120 Plasma 15 Number of
Page 29 and 30:
KCE Reports 120 Plasma 17 Table 4:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
KCE Reports 120 Plasma 23 Role of t
Page 37 and 38:
KCE Reports 120 Plasma 25 2.1.3.2 P
Page 39 and 40:
KCE Reports 120 Plasma 27 • 73% o
Page 41 and 42:
KCE Reports 120 Plasma 29 2.2 TRANS
Page 43 and 44:
KCE Reports 120 Plasma 31 Figure 6:
Page 45 and 46:
KCE Reports 120 Plasma 33 GEOGRAPHI
Page 47 and 48:
KCE Reports 120 Plasma 35 It is sur
Page 49 and 50:
KCE Reports 120 Plasma 37 Plasma fr
Page 51 and 52:
KCE Reports 120 Plasma 39 2.3 LIMIT
Page 53 and 54:
Page 55 and 56:
KCE Reports 120 Plasma 43 3.2 INDIC
Page 57 and 58:
KCE Reports 120 Plasma 45 Subcutane
Page 59 and 60:
Page 61 and 62:
KCE Reports 120 Plasma 49 3.2.2 Evi
Page 63 and 64:
KCE Reports 120 Plasma 51 Search re
Page 65 and 66:
KCE Reports 120 Plasma 53 CIDP IG i
Page 67 and 68:
KCE Reports 120 Plasma 55 • IG re
Page 69 and 70:
KCE Reports 120 Plasma 57 Solid org
Page 71 and 72:
KCE Reports 120 Plasma 59 A Cochran
Page 73 and 74:
KCE Reports 120 Plasma 61 • In ch
Page 75 and 76:
KCE Reports 120 Plasma 63 Two small
Page 77 and 78:
KCE Reports 120 Plasma 65 was lower
Page 79 and 80:
KCE Reports 120 Plasma 67 Three RCT
Page 81 and 82:
KCE Reports 120 Plasma 69 Severe se
Page 83 and 84:
KCE Reports 120 Plasma 71 The analy
Page 85 and 86:
KCE Reports 120 Plasma 73 3.3.1.2 T
Page 87 and 88:
KCE Reports 120 Plasma 75 Figure 7:
Page 89 and 90:
KCE Reports 120 Plasma 77 Figure 10
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
KCE Reports 120 Plasma 83 • For b
Page 97 and 98:
KCE Reports 120 Plasma 85 3.3.2.6 L
Page 99 and 100:
KCE Reports 120 Plasma 87 • The p
Page 101 and 102:
KCE Reports 120 Plasma 89 In Belgiu
Page 103 and 104:
KCE Reports 120 Plasma 91 Multifoca
Page 105 and 106:
KCE Reports 120 Plasma 93 Based on
Page 107 and 108:
KCE Reports 120 Plasma 95 Disease /
Page 109 and 110:
KCE Reports 120 Plasma 97 3.3.4 Exp
Page 111 and 112:
KCE Reports 120 Plasma 99 Figure 12
Page 113 and 114: KCE Reports 120 Plasma 101 Key poin
Page 115 and 116: KCE Reports 120 Plasma 103 Key poin
Page 117 and 118: KCE Reports 120 Plasma 105 • Conf
Page 119 and 120: KCE Reports 120 Plasma 107 As far a
Page 121 and 122: KCE Reports 120 Plasma 109 Followin
Page 123 and 124: KCE Reports 120 Plasma 111 4.3 HOW
Page 125 and 126: KCE Reports 120 Plasma 113 Improvin
Page 127 and 128: KCE Reports 120 Plasma 115 4.3.2 St
Page 129 and 130: KCE Reports 120 Plasma 117 4.4 CONC
Page 131 and 132: KCE Reports 120 Plasma 119 FAVOURIN
Page 133 and 134: KCE Reports 120 Plasma 121 APPENDIX
Page 135 and 136: KCE Reports 120 Plasma 123 For othe
Page 137 and 138: KCE Reports 120 Plasma 125 Table 48
Page 143 and 144: KCE Reports 120 Plasma 131 Distribu
Page 145 and 146: KCE Reports 120 Plasma 133 • Conv
Page 149 and 150: KCE Reports 120 Plasma 137 6 REFERE
Page 151 and 152: KCE Reports 120 Plasma 139 41. Pruz
Page 153 and 154: KCE Reports 120 Plasma 141 82. Comi
Page 155 and 156: KCE Reports 120 Plasma 143 123. Cre
Page 157 and 158: KCE Reports 120 Plasma 145 165. Cua
Page 159 and 160: This page is left intentionally bla
Page 161 and 162: KCE reports 1. Efficacité et renta
Page 163: 73. Financement du programme de soi
show all

The report is available in English with a French summary - KCE

Create successful ePaper yourself

Delete template?

Save as template?